Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542838 · ClinicalTrials.gov registry record · Phase 1
Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis
A Phase 1 study, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT03542838 is a Phase 1 study that has completed, run by Sorrento Therapeutics. The registered enrollment target is 94 participants.
The verdict
NCT03542838, a Phase 1 study, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
Interventions
- DRUG Resiniferatoxin
- DRUG Saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2021-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542838
The ClinicalTrials.gov registry entry for NCT03542838 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Resiniferatoxin is the first listed.
NCT03542838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542838 about?
NCT03542838 is a clinical study titled "Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis". This study evaluates the safety of resiniferatoxin in patients with moderate to severe knee pain due to osteoarthritis.
What is the current status of trial NCT03542838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2018-07-12. Estimated completion is 2021-02-11.
What interventions are being tested in trial NCT03542838?
The interventions under investigation include: Resiniferatoxin (DRUG), Saline (DRUG).
Who is sponsoring clinical trial NCT03542838?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.